Monopar Therapeutics, Inc.
(NASDAQ : MNPR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.47%149.710.0%$1388.80m
NVAXNovavax, Inc. -10.27%75.9678.2%$521.47m
AMGNAmgen, Inc. -2.25%222.591.4%$501.20m
BIIBBiogen, Inc. 0.22%221.011.8%$497.88m
GILDGilead Sciences, Inc. -1.42%67.541.0%$485.06m
BNTXBioNTech SE -0.37%146.950.0%$411.97m
REGNRegeneron Pharmaceuticals, Inc. -1.36%612.952.7%$397.26m
ILMNIllumina, Inc. -2.20%357.903.3%$370.53m
VRTXVertex Pharmaceuticals, Inc. -0.52%226.901.9%$339.19m
SNSSSunesis Pharmaceuticals, Inc. 1.13%2.680.7%$187.34m
EXASEXACT Sciences Corp. -2.38%72.2717.9%$164.65m
ARNAArena Pharmaceuticals, Inc. -0.66%89.8813.7%$130.50m
INCYIncyte Corp. -0.63%74.322.4%$129.36m
ALNYAlnylam Pharmaceuticals, Inc. -1.33%134.608.2%$123.34m
BMRNBioMarin Pharmaceutical, Inc. 0.07%84.714.2%$103.25m

Company Profile

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The firm engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.